Compare Mesoblast Limited (MESO) vs United Airlines Holdings Inc (UAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs United Airlines Holdings Inc — how do they compare? Mesoblast Limited trades at $16.38 (market cap $2.17B), while United Airlines Holdings Inc trades at $118.05 (market cap $38.15B). The key difference: United Airlines Holdings Inc is far larger — about 17.6× Mesoblast Limited's market cap, and United Airlines Holdings Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| MESO | UAL | |
|---|---|---|
Market Cap | $2.17B | $38.15B |
Sector | Technology | Industrials |
52-Week High | $20.96 | $136.11 |
52-Week Low | $12.88 | $84.57 |
Enterprise Value | $2.17B | $55.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $36 million for Ryoncil, showing strong commercial progress, but maintains a net income margin of -144.33% with significant losses. Recent news highlights pivotal Phase 3 trial milestones for chronic low back pain treatment and a $50 million non-dilutive financing draw.
Outlook is mixed: bullish analyst sentiment and clinical advancements offer upside potential, but high cash burn and persistent losses pose substantial risks. Investors should weigh the company's growth trajectory against its financial sustainability and regulatory milestones.
United Airlines (UAL) trades at $117.68, up 1.97% on the day, with a bullish technical signal and strong analyst support. The company has consistently beaten earnings estimates, with Q2 2026 EPS of $1.99 exceeding expectations. Revenue growth is robust, reaching $59.07B in 2025, and profitability metrics like a 5.56% net income margin and 23.25% ROE reflect operational strength. Recent news highlights labor agreements and resilient travel demand despite fuel cost pressures.
The outlook for UAL is positive, driven by strong travel demand and premium revenue growth, with a consensus price target of $163.75 implying significant upside. Risks include volatile fuel prices and operational disruptions, but the company's guidance for 2026 EPS of $9–$11 and improving cash flow trends support a favorable investment case for growth-oriented investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About United Airlines Holdings Inc
United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →
